Open AccessPrognostic factors for patients treated with abiraterone
Author(s) -
Cecília Alvim,
André Mansinho,
R. Paiva,
Rita Brás,
P. Semedo,
Soraia Lobo-Martins,
Cristina Ponte,
Daniela Macedo,
Leonor Ribeiro,
Jorge dos Reis,
Isabel Fernandes,
Luís Costa
Publication year - 2020
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2019-0079
Subject(s) - abiraterone acetate , medicine , hazard ratio , prostate cancer , oncology , retrospective cohort study , prostate specific antigen , multivariate analysis , proportional hazards model , progression free survival , overall survival , cancer , gastroenterology , urology , androgen deprivation therapy , confidence interval
Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.